Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity

Abstract

We and others have previously demonstrated that (chronic) interleukin (IL)-12 gene therapy delivered intratumorally through ex vivo gene-engineered dendritic cell (DC) is competent to promote the regression of established murine tumors. In this report, we have developed a conditional expression system (rAd.RheoIL12) to determine the temporal requirements of transgenic IL-12p70 production by administered DC on therapeutic outcome in a subcutaneous B16 melanoma model. DCs infected with rAd.RheoIL12 (DC.RheoIL12) secreted IL-12p70 in a tightly regulated fashion in response to a synthetic diacylhydrazine small molecule ligand in vitro, and the treatment benefit of DC.RheoIL12 delivered into B16 lesions was strictly ligand dependent in vivo. Indeed, DC.RheoIL12-based therapy promoted the regression of established day 7 B16 tumor lesions after intratumoral injection, provided that ligand administration occurred within 24 h of DC injection and was sustained for approximately 5 or more days. Treatment efficacy was correlated to the magnitude of systemic anti-B16 CD8+ T cells cross-primed in vivo, which in turn, appeared dependent on the early enhanced in vivo survival of adoptively transferred DC.RheoIL12 in tumor and tumor-draining lymph nodes. The unique safety feature of DC.RheoIL12 application was emphasized in a combined treatment model with rIL-2, where profound TNF-α-associated toxicity could be ameliorated upon discontinuation of activating ligand administration.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Purchase on Springer Link

Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3: 133–146.

    Article  CAS  Google Scholar 

  2. Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3: 409–417.

    CAS  PubMed  Google Scholar 

  3. Triozzi P, Allen KO, Carlisle RR, Craig M, LoBuglio AF, Conry RM . Phase I study of the intratumoral administration of recombinant canarypox viruses expressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res 2005; 11: 4168–4175.

    Article  CAS  Google Scholar 

  4. Sangro B, Mazzolini G, Ruiz J, Harraiz M, Quiroga J, Herrero I et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004; 22: 1389–1397.

    Article  CAS  Google Scholar 

  5. Heinzerling L, Burg G, Dummer R, Maier T, Oberbolzer PA, Schultz J et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16: 35–48.

    Article  CAS  Google Scholar 

  6. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671–684.

    Article  CAS  Google Scholar 

  7. Mazzolini G, Alfaro C, Sangro B, Feijoo E, Ruiz J, Benito A et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005; 23: 999–1010.

    Article  CAS  Google Scholar 

  8. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N et al. Cross-priming of naive CD8+ T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192: 1535–1544.

    Article  CAS  Google Scholar 

  9. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD et al. Local administration of IL-12-transfected dendritic cells induces anti-tumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2: 337–349.

    Article  CAS  Google Scholar 

  10. Yamanaka R, Zullo SA, Ramsey J, Yajima N, Tsuchiya N, Tanaka R et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002; 97: 611–618.

    Article  CAS  Google Scholar 

  11. Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL et al. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res 2003; 63: 6378–6386.

    CAS  PubMed  Google Scholar 

  12. Kumar P, Katakam AK . RheoSwitch System: a highly sensitive ecdysone receptor-based gene regulation system induced by synthetic small-molecule ligands. In: Friedman T, Rossi J (eds). Gene Transfer: Delivery and Expression of DNA and RNA. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2007: 643–651.

    Google Scholar 

  13. Itoh T, Storkus WJ, Gorelik E, Lotze MT . Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J Immunol 1994; 153: 1202–1215.

    CAS  PubMed  Google Scholar 

  14. Carson WE, Yu H, Dierksheide J, Pfeffer K, Bouchard P, Clark R et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162: 4943–4951.

    CAS  PubMed  Google Scholar 

  15. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105–2116.

    Article  CAS  Google Scholar 

  16. Chada S, Ramesh R, Mhashilkar AM . Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5: 463–474.

    CAS  PubMed  Google Scholar 

  17. Svane IM, Boesen M, Engel AM . The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors—lessons from normal and immunodeficient mice. Med Oncol 1999; 16: 223–238.

    Article  CAS  Google Scholar 

  18. Faure F, Even J, Kourilsky P . Tumor-specific immune response: current in vitro analyses may not reflect the in vivo immune status. Crit Rev Immunol 1998; 18: 77–86.

    Article  CAS  Google Scholar 

  19. Sangro B, Melero I, Qian C, Prieto J . Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573–581.

    Article  CAS  Google Scholar 

  20. Wigginton JM, Wiltrout RH . IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther 2: 513–524.

  21. Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G et al. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-γ production and STAT-mediated signal transduction. Blood 2000; 96: 1465–1473.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Dr Amy Wesa for her careful review of this work and suggestions made during the preparation of this paper.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to W J Storkus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Komita, H., Zhao, X., Katakam, A. et al. Conditional interleukin-12 gene therapy promotes safe and effective antitumor immunity. Cancer Gene Ther 16, 883–891 (2009). https://doi.org/10.1038/cgt.2009.33

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2009.33

Keywords

This article is cited by

Search

Quick links